Suggested remit: To appraise the clinical and cost effectiveness of tislelizumab within its marketing authorisation for treating untreated recurrent or metastatic nasopharyngeal cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6304
Provisional Schedule
- Committee meeting:
- 13 January 2027
- Expected publication:
- 13 May 2027
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- Liverpool Reviews and Implementation Group, University of Liverpool
Stakeholders
- Companies sponsors
- BeOne Medicines (tislelizumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Barretts UK
- Black Health Agency for Equality
- Cancer Black Care
- Cancer Laryngectomee Trust
- Cancer52
- Changing Faces
- Get-A-Head
- Head and Neck Cancer UK
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Let’s Face it
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Mouth Cancer Foundation
- National Association of Laryngectomee Clubs
- OG Support
- OPA Cancer Charity Oesophageal and Gastric Support
- Oracle Head and Neck Cancer
- Oral Health Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Swallows Head & Neck Cancer Support Group
- Tenovus Cancer Care
- Professional groups
- Association of Cancer Physicians
- British Association of Head and Neck Oncologists
- British Association of Head and Neck Oncology Nurses
- British Association of Oral and Maxillofacial Surgeons
- British Association of Otorhinolaryngologists
- British Geriatrics Society
- British Oculoplastic Surgery Society (BOPSS)
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Skull Base Society
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society of Radiographers
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Amarox (cisplatin, capecitabine)
- Bristol Myers Squibb (paclitaxel)
- Dr Reddys Laboratories (capecitabine)
- Genus (paclitaxel)
- Glenmark Pharmaceuticals (capecitabine)
- Hospira UK (carboplatin, cisplatin, gemcitabine, fluorouracil, docetaxel, paclitaxel)
- Leo Pharma (toripalimab)
- Medac Pharma (fluorouracil)
- Sandoz Ltd (cisplatin)
- Seacross Pharmaceuticals (docetaxel, paclitaxel)
- Sun Pharmaceuticals (gemcitabine)
- Synchrony Pharma (gemcitabine)
- Teva UK (paclitaxel)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Genomics England
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Institute for Health Research
- Oracle Cancer
- Saving Faces
- The Head and Neck Cancer Foundation
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 June 2026 | Invitation to participate |
| 27 March 2026 - 28 April 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6304 |
| 27 March 2026 | In progress. Scoping commencing |
| 19 December 2025 | Note - Note added to the project documents |
| 01 December 2023 | Note - Note added to the project documents |
| 29 July 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual